Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las indicaciones geográficas protegen el nombre de un producto originario de una zona geográfica, a la cual le debe una determinada calidad, reputación u otra característica. Descubre qué son, en qué consiste su procedimiento de registro y qué beneficios conceden.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
113
resultados
Última actualización
06/05/2026 [07:09:00]
Resultados 75 a 100 de 113
Resumen de: US20260088150A1
Techniques disclosed herein relate to operating a fluid delivery device in a personalized manner based at least in part on historical data of a patient. In some embodiments, the techniques involve obtaining historical meal data for the patient associated with historical meal events for the patient; determining a meal content based at least in part on the historical meal data; obtaining nutritional information associated with the meal content and historical meal events for the patient; determining, by a control system, a dosage of insulin based at least in part on the nutritional information and the historical meal events; and operating, by the control system, an actuation arrangement of the infusion device to deliver the dosage of the insulin to the patient.
Resumen de: WO2026064554A1
Provided herein are methods of treating various eye disorders, including, for example, wet age-related macular degeneration (wAMD) or diabetic retinopathy (DR), using an anti-VEGF therapy, such as an anti-VEGF antibody conjugate.
Resumen de: US20260083909A1
A reinforcement learning process with self attention is used for insulin dosing decisions in an automated medical system. The State-Action-Reward-Next State (SARS) sequence is used. The state represents the current condition, including recent continuous glucose monitoring readings, insulin doses, meal information, and potentially other relevant factors like time of day or physical activity levels. Based on this state, the agent takes an action by deciding on an insulin dose. It then receives a reward, a numerical value quantifying the quality of the action, based on resulting glucose levels and their proximity to the target range. This leads to a new state, and the process repeats. Through this iterative process, the algorithm updates the neural network weights, allowing the agent to learn which actions lead to better outcomes in different states.
Resumen de: WO2026062700A1
The present disclosure relates to a system and method to predict the post- prandial glucose response in the individuals type 2 diabetes mellitus (T2DM) in India by taking sample of patients with T2DM from various locations across India and fitting them with continuous glucose monitors (CGM) and calculating the postprandial glucose response based on the different meal intakes by the patients. The present disclosure further relates to the utilization of k-means clustering models to classify food types based on nutritional information and classification of patients. The present disclosure also relates to utilizing XGBoost to predict postprandial blood glucose responses based on patient phenotypes and food categories and providing personalized recommendations taking into account meal type, preferences, and regional influences which would allow patients with T2DM to eat and drink foods to maintain their blood sugar within prescribed limits and prevent disease progression.
Resumen de: US20260083363A1
This document describes medical systems for detecting biological analytes. For example, this document describes sensors for the continuous monitoring of biological analytes, such as glucose and/or lactate, in aqueous solutions and body fluids (e.g., blood) based on a readout of fluorescence or luminescence signals.WO
Resumen de: US20260089162A1
Systems, devices, and methods are disclosed for wireless communication of analyte data. In embodiments, a method of using a diabetes management partner interface to configure an analyte sensor system for wireless communication with a plurality of partner devices is provided. The method includes the analyte sensor system receiving authorization to provide one of the partner devices with access to a set of configuration parameters via the diabetes management partner interface. The set of configuration parameters is stored in a memory of the analyte sensor system. The method also includes, responsive to input received from the one partner device via the diabetes management partner interface, the analyte sensor system setting or causing a modification to the set of configuration parameters, according to a system requirement of the one partner device.
Resumen de: EP4671882A2
The present disclosure relates to a system for closed loop control of glycemia. In one arrangement, the system comprises: an insulin delivery device; a user interface for inputting patient data, the patient data including a basal insulin profile, an insulin-to-carbohydrate ratio, and meal data; and a controller in communication with the user interface and the insulin delivery device and configured to receive glucose data. The controller is further configured to execute: estimating an amount of active insulin in the patient, the active insulin not including the basal insulin profile, determining a meal carbohydrate value from the meal data, estimating a physiological glucose for the patient and a rate of change of physiological glucose based in part on the glucose data, determining an attenuation factor based on the physiological glucose and the rate of change of the physiological glucose, determining a meal bolus based on meal data, the insulin-to-carbohydrate ratio, and the determined attenuation factor, modifying the determined meal bolus based on the estimated amount of active insulin in the patient, and transmitting a request to deliver the modified meal bolus to the insulin delivery device.
Resumen de: EP4715836A1
A meal monitoring apparatus according to an embodiment of the present invention includes a data receiving unit configured to receive measurement data of parameters related to an ear of a target object and blood glucose data of the target object; a first estimated time calculating unit configured to calculate a first estimated time estimated as a food intake activity time of the target object based on the measurement data; a second estimated time calculating unit configured to calculate a second estimated time estimated as a glucose absorption time of the target object based on the blood glucose data; and a meal time calculating unit configured to calculate a meal time of the target object based on the first estimated time and the second estimated time.
Resumen de: EP4715554A2
One or more embodiments of the present disclosure may include an insulin delivery system that includes an insulin delivery device, a user interface that includes multiple user-selectable icons or buttons each representing different meal characteristics, memory to store one or more user-specific dosage parameter, and a processor in communication with the memory and adapted to receive blood glucose data. The processor may also be adapted to determine initial meal characteristics associated with each of the user-selectable icons or buttons based on at least one of the user-specific dosage parameters. The processor may also be adapted to update the meal characteristics associated with each of the user-selectable icons or buttons based upon the blood glucose data.
Resumen de: US20260077116A1
An infusion system is disclosed comprising: a device for delivering insulin to a user, the device including a reservoir and a micropump for pumping the insulin from the reservoir into tissue of a user; and a cartridge for securing a cartridge insert that includes (a) an infusion needle configured to infuse the insulin and introduce a CGM sensor into the user or (b) an introducer needle for introducing an infusion catheter and the CGM sensor into the user, the cartridge configured to move from (1) a first position, wherein the infusion needle or an introducer needle is above the tissue of the user to (2) an second position, wherein the infusion needle or the introducer needle is in a deployed position inserted into tissue of the user, wherein the cartridge includes a locking mechanism to lock the cartridge insert into the cartridge.
Resumen de: WO2026060397A2
An analyte sensor system may include an analyte sensor configured to generate a raw sensor signal associated with an analyte concentration of a host. Sensor electronics may be configured to generate estimated analyte values from the raw sensor signal, determine a rate of change for the estimated analyte values or the raw signal, determine a working electrode temperature, and determine an elapsed time since sensor insertion. The sensor electronics may improve sensor performance by determining a prediction horizon as a function of at least one of the elapsed time and the working electrode temperature, determining a time-lag- compensated estimated analyte value for one of the estimated analyte values as a function of the determined prediction horizon and the rate-of-change, and adjusting estimated analyte values by applying a correction that is a function of the estimated analyte values.
Resumen de: US20260076628A1
A system is provided comprising external device(s), tracking device(s) configured to generate blood glucose level data for tracked individual(s), and an alert device for management of alerts generated at the external device(s). The alert device comprises processor(s) and memory device(s). The memory device(s) comprise computer readable code that, when executed by the processor(s), causes the processor(s) to receive input data comprising blood glucose level data received from the tracking device(s), to determine an alert setting for an alert to be generated at an external device of the external device(s) based on the input data, and to generate a signal that causes the alert to be generated at the external device. The alert setting includes an identification of the external device where the alert is to be generated, an alert magnitude, and/or the alert type, with the alert type including an audible alert, a haptic alert, and/or a visual alert.
Resumen de: WO2026059033A1
Disclosed, according to various embodiments of the present invention, is a method for adjusting an insulin injection amount based on predicted blood glucose. The method may comprise the steps of: predicting a future blood glucose value on the basis of the current blood glucose value and an insulin injection history; determining a future blood glucose state on the basis of the future blood glucose value and a predefined correction factor; and adjusting an insulin injection amount so as to correspond to the future blood glucose state.
Resumen de: US20260076591A1
Systems, devices and methods are provided for incorporating a medication delivery device into an integrated management system. The integrated management system may be an integrated diabetes management system and may include a glucose monitor, a connected insulin pen, and software. The integrated management system may produce a plurality of reports that may include data related to analyte levels (e.g., glucose levels) and medication delivered (e.g., insulin delivered). The integrated system may also include a mode in which certain types of data are no longer shared and/or stored if the user is not signed into an account. The types of data shared and/or stored when the user is not signed into an account may differ from the types of data shared and/or stored when the user is signed into an account.
Resumen de: AU2026201602A1
Systems and methods disclosed provide ways for Health Care Professionals (HCPs) to be involved in initial patient system set up so that the data received is truly transformative, such that the patient not just understands what all the various numbers mean but also how the data can be used. For example, in one implementation, a CGM device is configured for use by a HCP, and includes a housing and a circuit configured to receive a signal from a transmitter coupled to an indwelling glucose sensor. A calibration module converts the received signal into clinical units. A user interface is provided that is configured to display a measured glucose concentration in the clinical units. The user interface is further configured to receive input data about a patient level, where the input data about the patient level causes the device to operate in a mode appropriate to the patient level. ar a r
Resumen de: EP4712100A2
0001 An Adaptive Advisory Control (AA Control) interactive process involving algorithm-based assessment and communication of physiologic and behavioral parameters and patterns assists patients with diabetes with the optimization of their glycemic control. The method and system may uses all available sources of information about the patient; (i) EO Data (e.g. self-monitoring of blood glucose (SMBG) and CMG), (ii) Insulin Data (e.g. insulin pump log files or patient treatment records), and (iii) Patient Self Reporting Data (e.g. self treatment behaviors, meals, and exercise) to: retroactively assess the risk of hypoglycemia, retroactively assess risk-based reduction of insulin delivery, and then report to the patient how a risk-based insulin reduction system would have acted consistently to prevent hypoglycemia.
Resumen de: EP4712093A2
A method may include obtaining blood glucose level readings over a diurnal period for each of a plurality of days and determining an estimated variability of the blood glucose levels over the diurnal period for the plurality of days. The method may also include modifying, based on the estimated variability of the blood glucose level, a target blood glucose level to a modified target blood glucose level, and delivering insulin, using an insulin pump, during the diurnal period based on the modified target blood glucose level.
Resumen de: EP4710855A2
A method for optional external calibration of a calibration-free glucose sensor uses values of measured working electrode current (Isig) and EIS data to calculate a final sensor glucose (SG) value. Counter electrode voltage (Ventr) may also be used as an input. Raw Isig and Vcntr values may be preprocessed, and low-pass filtering, averaging, and/or feature generation may be applied. SG values may be generated using one or more models for predicting SG calculations. Complex redundancy may be employed to take operational advantage of disparate characteristics of two or more dissimilar, or non-identical, sensors, including, e.g., characteristics relating to hydration, stabilization, and durability of such sensors. Fusion algorithms, EIS, and advanced Application Specific Integrated Circuits (ASICs) may be used to implement use of such redundant glucose sensors, devices, and sensor systems in such a way as to bridge the gaps between fast start-up, sensor longevity, and accuracy of calibration-free algorithms.
Resumen de: US12576209B1
A housing for hypodermic device including a housing assembly, a hypodermic device housed therein, twist off top and bottom caps. The housing assembly includes an upper and lower ends, exterior and interior walls. The exterior and interior walls definine a vacuum sealed in-between space, and the interior wall defines an interior cavity. The top and bottom caps include first and second tabs, respectively. The hypodermic device has proximal and distal ends. The hypodermic device includes auto injectors such as epinephrine auto injector, insulin auto injector or similar. The exterior and interior walls are vacuum sealed layers made of a rigid material that protect the hypodermic device from impact and accidental activation and keep the hypodermic device at a range of temperature for a longer period of time. A ring attachment is adjacent to the upper end, and it secures to backpacks, purses, garments or similar.
Resumen de: US20260069780A1
Techniques disclosed herein related to controlling insulin delivery. In some embodiments, the techniques may involve delivering insulin via an insulin infusion device according to a closed-loop mode of delivery. The techniques may further involve determining, at a first time point, insulin delivery is to be switched from the closed-loop mode of delivery to a second mode of delivery. The techniques may further involve switching operation of the insulin infusion device to the second mode of delivery such that insulin is delivered via the insulin infusion device according to the second mode of delivery.
Resumen de: WO2026054488A1
The present invention relates to a method for managing a diabetic patient using a continuous glucose monitor, the method being characterized by comprising: a data reception step of receiving measurement data from a continuous glucose monitor; a data calculation step of calculating a sensor wearing time, a time within a specific glucose range, a time less than a first glucose value, a time greater than a second glucose value, EhyperE (whether a glucose level continuously exceeds 250 mg/dL for 2 hours or more), a time during which a glucose level is less than 54 mg/dL, and food intake time detection (FITD) by using the measurement data; and a data classification step of including a matrix part for classifying into one or more cases according to a time ratio, over a period of one week, of the sensor wearing time, the time within a specific glucose range, the time less than a first glucose value, the time greater than a second glucose value, EhyperE (whether a glucose level continuously exceeds 250 mg/dL for 2 hours or more), the time during which a glucose level is less than 54 mg/dL, and the food intake time detection, and an insulin and lifestyle correction part for classifying into one or more cases according to the number of times a predetermined glucose level occurs in a predetermined time period.
Resumen de: US20260069776A1
Provided are a method, apparatus, and computer program for providing a notification according to a period of use of a drug infusion device. A time point at which the drug infusion device switches from an inactive mode to an active mode may be determined as a use start time point. Also, an impending expiration notification indicating that expiration of a period of use of the drug infusion device is imminent may be provided at a first time point after a certain period from the use start time point, based on a usable period and a user set time of the drug infusion device. In addition, an expiration notification indicating that the period of use of the drug infusion device has expired may be provided at a second time point after the usable period from the use start time point.
Resumen de: WO2026055546A2
Methods, systems and devices for providing health information to an individual. Methods may include predicting a subject's glucose sensitivity risk based on recorded sleep brain activity signals, and optionally providing an output to the subject based on the predicted glucose sensitivity risk. Methods may include providing personalized proactive behavioral guidance for a subject for an awake period following a sleep period, the proactive behavior guidance based on at least one of predicted glucose sensitivity risk or quality of sleep.
Resumen de: US20260069781A1
The exemplary embodiments attempt to identify impending hypoglycemia and/or hyperglycemia and take measures to prevent the hypoglycemia or hyperglycemia. Exemplary embodiments may provide a drug delivery system for delivering insulin and glucagon as needed by a user of the drug delivery system. The drug delivery system may deploy a control system that controls the automated delivery of insulin and glucagon to a patient by the drug delivery system. The control system seeks among other goals to avoid the user experiencing hypoglycemia or hyperglycemia. The control system may employ a clinical decision support algorithm as is described below to control delivery of insulin and glucagon to reduce the risk of hypoglycemia or hyperglycemia and to provide alerts to the user when needed. The control system assesses whether the drug delivery system can respond enough to avoid hypoglycemia or hyperglycemia and generates alerts when manual action is needed to avoid hypoglycemia or hyperglycemia.
Nº publicación: US20260069173A1 12/03/2026
Solicitante:
DEXCOM INC [US]
Dexcom, Inc
Resumen de: US20260069173A1
Various examples are directed to a glucose sensor comprising a working electrode to support an oxidation reaction and a reference electrode to support a redox reaction. The reference electrode may comprise silver and silver chloride. The Glucose sensor may also comprise an anti-mineralization agent positioned at the reference electrode to reduce formation of calcium carbonate at the reference electrode.
BOPI
Sede Electrónica
